Business
Tenon(R) Medical Reports Fourth Quarter and Full Year 2025 Financial Results
~ Fourth Quarter 2025 Revenue of $1.5 Million, a 92% Increase Compared to Prior Year ~~ Record Full Year 2025 Revenue of $3.9 Million, a 20% Increase compared
About this update from Tenon Medical, Inc.
[{"type":"text","content":"~ Fourth Quarter 2025 Revenue of $1.5 Million, a 92% Increase Compared to Prior Year ~~ Record Full Year 2025 Revenue of $3.9 Million, a 20% Increase compared to Prior Year, Driven by Strong Second Half Momentum ~~ Record Full Year 2025 Gross Profit of $2.4 Million, a 38% Increase Compared to Prior Year ~~ Secured FDA 510(k) Clearance For its Next-Generation SImmetry®+ SI Joint Fusion System ~~ Completed Initial SImmetry®+ Procedures at Centers of Excellence, Advancing Commercial Rollout and Supporting Early Surgeon Adoption ~ LOS GATOS, CA / ACCESS Newswire / March 19, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) (\"Tenon Medical\" or the \"Company\"), a company redefining care for patients suffering from sacro-pelvic disorders, today reported financial results for the fourth quarter and year ended December 31, 2025.Financial Results and Business UpdatesFourth Quarter 2025 Results:Record revenue of $1.5 million, an increase of 92% compared to $0.8 million in the fourth quarter of 2024.Gross profit of $1.0 million, an increase of 188% compared to $0.4 million in the fourth quarter of 2024.Gross margin of 69%, a twenty-three percentage point improvement from 46% in the fourth quarter of 2024.Full Year 2025 Results:Record revenue of $3.9 million, a 20% increase compared to $3.3 million in 2024.Gross profit of $2.4 million, a 38% increase compared to $1.7 million in 2024.Gross margin of 60%, an eight percentage point improvement from 52% in 2024.Tenon received FDA 510(k) clearance for its next-generation SImmetry®+ SI Joint Fusion System, expanding its portfolio to include a complementary lateral approach. This clearance broadens the Company's addressable market and enhances its ability to support diverse surgeon preferences and patient anatomies.The Company completed a $2.85 million At-The-Market PIPE financing in Q4 2025 to strengthen its balance sheet and support strategic growth initiatives. The additional capital provides flexibility to advance product launches, expand commercial operations, and fund clinical development efforts.Tenon successfully completed initial SImmetry®+ procedures at Centers of Excellence, marking an important step in the system's commercial rollout. Early clinical experience reinforces surgeon confidence and supports broader market expansion in the quarters ahead.Hosted 24 physicians in targeted training se...